Also trades as: INCPF (OTC) · $vol 0M
9969.HK HKSE
InnoCare Pharma Limited
1W: -6.1%
1M: -5.7%
3M: -2.6%
YTD: +3.3%
1Y: -30.5%
3Y: +68.1%
5Y: -54.9%
HK$13.63 ($1.74)
-1.16 (-7.84%)
Weekly Expected Move ±10.9%
HK$11
HK$12
HK$14
HK$15
HK$17
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$199M
+154.5% ▲
Capital Expenditures
$68M
+12.6% ▲
5Y CAGR: -22.9%
Free Cash Flow
$131M
+129.5% ▲
Dividends Paid
$0
+100.0% ▲
Buybacks
$16M
-21.5% ▼
Net Change in Cash
$1.1B
+132.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$20M | -$894M | -$644M | -$453M | $626M |
| Depreciation & Amort. | $32M | $68M | $93M | $0 | $115M |
| Stock-Based Comp. | $126M | $129M | $65M | -$11M | $0 |
| Change in Working Capital | $120M | -$75M | -$244M | -$18M | -$613M |
| Other Non-Cash Items | -$132M | $205M | $59M | $116M | $71M |
| Operating Cash Flow | $167M | -$566M | -$671M | -$366M | $199M |
| — Investing Activities — | |||||
| Capital Expenditures | -$167M | -$370M | -$255M | $0 | -$68M |
| Acquisitions (Net) | -$868K | -$20M | $1M | $0 | $24K |
| Investment Purchases | -$4.2B | -$1.8B | -$4.1B | $0 | -$13.1B |
| Investment Sales | $2.7B | $413M | $5.0B | $0 | $12.8B |
| Other Investing | -$4M | $75M | $6M | $1.1B | $0 |
| Investing Cash Flow | -$1.7B | -$1.7B | $667M | $1.1B | -$358M |
| — Financing Activities — | |||||
| Net Debt Issuance | $50M | $325M | $5M | $164M | $30M |
| Stock Repurchased | $0 | $0 | -$6M | -$13M | -$16M |
| Dividends Paid | $0 | -$3M | -$1M | -$363M | $0 |
| Other Financing | -$33M | -$150M | $4M | -$92M | -$46M |
| Financing Cash Flow | $2.5B | $3.1B | $1M | -$286M | -$33M |
| Net Change in Cash | $937M | $942M | $23M | $477M | $1.1B |
| Cash End of Period | $3.2B | $4.2B | $4.2B | $4.7B | $7.1B |
| Free Cash Flow | -$11K | -$936M | -$926M | -$444M | $131M |